NetSig: Network-based discovery from cancer genomes

Nature Methods

Volumn 15, Issue 1, 2018, Pages 61-66

  Horn, Heiko ^a,b   Lawrence, Michael S ^b,c   Chouinard, Candace R ^b   Shrestha, Yashaswi ^b   Hu, Jessica Xin ^a,b   Worstell, Elizabeth ^a,b   Shea, Emily ^b   Ilic, Nina ^b,d   Kim, Eejung ^b,d   Kamburov, Atanas ^b,c   Kashani, Alireza ^a,b   Hahn, William C ^b,d   Campbell, Joshua D ^b,e   Boehm, Jesse S ^b   Getz, Gad ^b,c   Lage, Kasper ^a,b,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B BETA; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CONTROLLED STUDY; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; GENOME ANALYSIS; HUMAN; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NETWORK LEARNING; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; TFDP2 GENE; TUMOR GENE; BIOLOGY; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; MUTATION; NEOPLASM; PROCEDURES;

CARCINOGENESIS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MUTATION; NEOPLASM PROTEINS; NEOPLASMS;

EID: 85040187966     PISSN: 15487091     EISSN: 15487105     Source Type: Journal    
DOI: 10.1038/nmeth.4514     Document Type: Article

References (33)

1. Garraway, L.A. & Lander, E.S. Lessons from the cancer genome. Cell 153, 17-37 (2013).
2. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
3. Frampton, G.M. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023-1031 (2013).
4. Roychowdhury, S. et al. Personalized oncology through integrative highthroughput sequencing: a pilot study. Sci. Transl. Med. 3, 111ra121 (2011).
5. Van Allen, E.M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140-1153 (2014).
6. Wagle, N. et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2, 82-93 (2012).
7. Gonzalez-Perez, A. & Lopez-Bigas, N. Functional impact bias reveals cancer drivers. Nucleic Acids Res. 40, e169 (2012).
8. Mermel, C.H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
9. Taylor, B.S. et al. Functional copy-number alterations in cancer. PLoS One 3, e3179 (2008).
10. Lohr, J.G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA 109, 3879-3884 (2012).
11. Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
12. Ciriello, G., Cerami, E., Sander, C. & Schultz, N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 22, 398-406 (2012).
13. Hofree, M., Shen, J.P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10, 1108-1115 (2013).
14. Leiserson, M.D.M. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47, 106-114 (2015).
15. Vandin, F., Upfal, E. & Raphael, B.J. Algorithms for detecting significantly mutated pathways in cancer. J. Comput. Biol. 18, 507-522 (2011).
16. Babur, O. et al. Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biol. 16, 45 (2015).
17. Miller, C.A., Settle, S.H., Sulman, E.P., Aldape, K.D. & Milosavljevic, A. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. BMC Med. Genomics 4, 34 (2011).
18. Yeang, C.-H., McCormick, F. & Levine, A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 22, 2605-2622 (2008).
19. Creixell, P. et al. Pathway and network analysis of cancer genomes. Nat. Methods 12, 615-621 (2015).
20. Lage, K. et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat. Biotechnol. 25, 309-316 (2007).
21. Li, T. et al. A scored human protein-protein interaction network to catalyze genomic interpretation. Nat. Methods 14, 61-64 (2016).
22. Berger, A.H. et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell 30, 214-228 (2016).
23. Boehm, J.S. et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129, 1065-1079 (2007).
24. Dunn, G.P. et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc. Natl. Acad. Sci. USA 111, 1102-1107 (2014).
25. Kim, E. et al. Systematic functional interrogation of rare cancer variants identifies oncogenic alleles. Cancer Discov. 6, 714-726 (2016).
26. Campbell, J.D. et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48, 607-616 (2016).
27. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
28. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
29. Marbach, D. et al. Tissue-specific regulatory circuits reveal variable modular perturbations across complex diseases. Nat. Methods 13, 366-370 (2016).
30. Lage, K. et al. A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc. Natl. Acad. Sci. USA 105, 20870-20875 (2008).
31. Rossin, E.J. et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet. 7, e1001273 (2011).
32. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
33. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).